🔥 Find me at MedicalDevicesGroup.net 🔥
3 min reading time
In this value-based healthcare world, providers put you in a bucket. Is yours:
I hadn’t thought of it as binary until I read https://medgroup.biz/VBHC from ICON plc.
Interestingly, whether you make an innovation or a commodity, it’s gonna be expensive.
Innovations require premarket approvals and comprehensive clinical and economic evidence packages.
Commodities require design, production, and distribution efficiencies to beat low-cost competitors.
Complicating matters, national health systems tend to favor long-term population outcomes, while private insurers often focus more on short-term costs related to specific acute care episodes. So how does that figure into your strategy?
• For EU markets, health technology assessment (HTA) organizations now require providers to report patient outcomes and broadened HTA criteria to include impact on total treatment costs. And you probably know about increased requirements for all the acronyms: MDRs, IVDRs, and EUDAMED.
And perhaps most valuable, a framework for assessing stakeholder value that considers what value would look like for each constituency.
Join me at https://medgroup.biz/digital to join the live event or request the replay.
Speakers from Syncera, Agnitio, Ascensia DiabetesCare, and Edwards Lifesciences.
Make it a great week.
As Medicare Advantage expands benefit design to include non-medical interventions such as “right equipment, right time” to support aging at home, will they look for outperforming products? Will DME/HME manufacturers invest in innovative products? Will payers/providers engage in rapid cycle testing to understand if a particular innovative product performs better than the commoditized products they currently cover?
Dymphy van der Wilk
Laurie Shollenberger Hurt
Marked as spam